Literature DB >> 33878323

Fabrication of rapidly separable microneedles for transdermal delivery of metformin on diabetic rats.

Tianqi Liu1, Guohua Jiang2, Gao Song1, Yanfang Sun3, Xueya Zhang1, Zhiyong Zeng1.   

Abstract

In this work, the rapidly separable microneedles (MNs) consisted of needle-tips and supporting bases have been fabricated by a step-by-step coating method. Poly (vinyl alcohol) (PVA) have been used to prepare the needle-tips of MNs in which they are capped on the solvable supporting bases consisted of sodium bicarbonate, poly (vinyl pyrolidone) (PVP), and tartaric acid (TA) (NaHCO3/PVP/TA). After insertion into the skin, the needle-tips can be separated rapidly from the patches within 90 s due to the generation of air bubbles in the supporting bases by the reaction between NaHCO3 and TA after absorption of tissue fluid, leading to the needle-tips remaining in the skin tissue. Metformin, a hypoglycemic drug, encapsulated in the needle-tips of MNs can be released due to swelling and decomposition of PVA by the absorption of tissue fluid. To investigate the pharmacological effect via transdermal delivery route, metformin-loaded MNs are applied on the diabetic SD rats induced by streptozotocin (STZ). They exhibit a longer hypoglycemic effect in vivo than that of subcutaneous injection. These results indicated the as-fabricated rapidly separable MNs present a promising platform for transdermal delivery of drugs against diabetic patients.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  diabetes; hypoglycemic effect; microneedles; transdermal delivery

Year:  2021        PMID: 33878323     DOI: 10.1016/j.xphs.2021.04.009

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  1 in total

1.  Transdermal Delivery of Metformin Utilizing Ionic Liquid Technology: Insight Into the Relationship Between Counterion Structures and Properties.

Authors:  Minghuang Hong; Qinglin Wang; Kai Wang; Jinghui Li; Ming-Hui Qi; Guo-Bin Ren
Journal:  Pharm Res       Date:  2022-09-28       Impact factor: 4.580

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.